{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:11:06Z","timestamp":1792631466936,"version":"4.5.0"},"reference-count":47,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Immunology"],"published-print":{"date-parts":[[2022,9,2]]},"DOI":"10.1080\/1744666x.2022.2106972","type":"journal-article","created":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T07:34:27Z","timestamp":1658907267000},"page":"879-888","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":13,"title":["Abdeg technology for the treatment of myasthenia gravis: efgartigimod drug experience"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5528-0658","authenticated-orcid":false,"given":"J\u00e9ssica Barreto Ribeiro","family":"Dos Santos","sequence":"first","affiliation":[{"name":"Department of Pharmacy and Nutrition, Health Economics and Technology Assessment Group; Center for Exact, Natural and Health Sciences, Federal University of Esp\u00edrito Santo, Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8299-4835","authenticated-orcid":false,"given":"Ros\u00e2ngela Maria","family":"Gomes","sequence":"additional","affiliation":[{"name":"Department of Management and Incorporation of Technologies and Innovation in Health; Secretariat of Science, Technology and Strategic Inputs; Ministry of Health of Brazil, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2550-7249","authenticated-orcid":false,"given":"Michael Ruberson Ribeiro","family":"da Silva","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Nutrition, Health Economics and Technology Assessment Group; Center for Exact, Natural and Health Sciences, Federal University of Esp\u00edrito Santo, Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,8,5]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2018.01.002"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00776"},{"key":"cit0003","unstructured":"De Haard J, Dreier T, Ulrichts P, et al. Use of FcRn antagonists for treatment of generalized myasthenia gravis. World Intellectual Property Organization patent WO 2019\/110823 A1. 2019 June. Available in: https:\/\/patents.google.com\/patent\/WO2019110823A1\/en."},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1159\/000279334"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.3233\/JND-140045"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1254.053"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181ad53c2"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2018.01.011"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-020-00443-w"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1111\/cen3.12180"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8045-z"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13503"},{"key":"cit0014","unstructured":"Brazil. Ministry of health. Ordinance n 11, of 2022 May 23. Approves the Clinical Protocol and Therapeutic Guidelines for Myasthenia Gravis. Available from: http:\/\/conitec.gov.br\/images\/Protocolos\/20220530_PORTAL_PCDT_Miastenia_Gravis.pdf"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2000.04.1003"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2017.06.009"},{"key":"cit0017","unstructured":"Food and Drug Administration [Internet]. United States: drugs@FDA: FDA-Approved Drugs. Vyvgart (efgartigimod). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761156s000lbl.pdf. Acceced on 2022 Feb 24"},{"key":"cit0018","unstructured":"Clinical Trials [Internet]. United States: clinical Trials. Efgartigimod; [cited 2022 Feb 24]. Available from: https:\/\/clinicaltrials.gov\/ct2\/home"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0402970101"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03052"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/282989"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003780"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1143"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25973"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911"},{"key":"cit0026","unstructured":"National Institute for Health. National Center for Advancing Translational Sciences. Inxight Drugs. Efgartigimod alfa. [cited 2022 Apr 6]. Available in: https:\/\/drugs.ncats.io\/substance\/961YV2O515"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.2210\/pdb7LBL\/pdb"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007600"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9"},{"key":"cit0030","volume-title":"American Academy of Neurology. AAN Annual Meeting","author":"Howard J"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01678-3"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206754"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-016-2556-3"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1177\/1756286421997381"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102366"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2013.05.004"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007605"},{"key":"cit0038","unstructured":"Argenx. Argenx announces positive topline phase 3 data from ADAPT-SC study evaluating subcutaneous efgartigimod for generalized myasthenia gravis. News release. March 22, 2022. Available from: https:\/\/www.argenx.com\/sites\/default\/files\/media-documents\/argenx_ADAPT-SC_TLR_Press_Release.pdf. Accessed 2022 May 23."},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211065406"},{"issue":"6","key":"cit0040","doi-asserted-by":"crossref","first-page":"e853","DOI":"10.1212\/WNL.0000000000011108","volume":"96","author":"Bril V","year":"2021","journal-title":"Neurology"},{"key":"cit0041","unstructured":"Clinical Trials [Internet]. United States: clinical Trials. Rozanolixizumab; [cited 2022 May 24]. Available from: https:\/\/clinicaltrials.gov\/ct2\/home"},{"key":"cit0042","unstructured":"Clinical Trials [Internet]. United States: clinical Trials. Nipocalimab; [cited 2022 May 24]. Available from: https:\/\/clinicaltrials.gov\/ct2\/home"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00345-9"},{"key":"cit0044","unstructured":"Clinical Trials [Internet]. United States: clinical Trials. Batoclimab; [cited 2022 May 24]. Available from: https:\/\/clinicaltrials.gov\/ct2\/home"},{"key":"cit0045","first-page":"682","volume":"5","author":"Sand KM","journal-title":"Front Immunol"},{"key":"cit0046","first-page":"00086","volume":"3","author":"Md AH","year":"2016","journal-title":"Urol Nephrol Open Access J"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2082946"}],"container-title":["Expert Review of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/1744666X.2022.2106972","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T00:42:10Z","timestamp":1700872930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/1744666X.2022.2106972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9,2]]}},"alternative-id":["10.1080\/1744666X.2022.2106972"],"URL":"https:\/\/doi.org\/10.1080\/1744666x.2022.2106972","relation":{},"ISSN":["1744-666X","1744-8409"],"issn-type":[{"value":"1744-666X","type":"print"},{"value":"1744-8409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierm20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierm20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-04-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}